|
|
|
Insider
Information: |
Dier Mardi |
Relationship: |
|
City: |
South San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
101,126 |
|
Indirect Shares
|
875 |
|
|
Direct
Value |
$5,026,869 |
|
|
Indirect Value
|
$3,588 |
|
|
Total
Shares |
102,001 |
|
|
Total
Value |
$5,030,456 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
2
|
0
|
|
|
|
Gain/Loss Ratio : |
-2.0
|
1.0
|
Percentage
Gain/Loss : |
-71.0%
|
18.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Portola Pharmaceuticals Inc |
PTLA |
EVP and CFO |
2020-07-02 |
0 |
|
0 |
Premium* |
|
Adamas Pharmaceuticals Inc |
ADMS |
Director |
2021-06-02 |
10,000 |
2020-06-03 |
0 |
Premium* |
|
Prelude Therapeutics Inc |
PRLD |
Director |
2020-09-29 |
10,000 |
2020-09-29 |
0 |
Premium* |
|
Ultragenyx Pharmaceutical Inc |
RARE |
CFO & Executive Vice P... |
2022-10-14 |
66,695 |
2020-10-12 |
0 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
CFO and CBO |
2023-05-09 |
5,556 |
2023-05-09 |
875 |
Premium* |
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-03-11 |
8,875 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
73 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2015-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2016-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
13,750 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2016-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
16,250 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP and CFO |
|
2017-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
15,625 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2018-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
10,625 |
10,625 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2018-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
5,859 |
118,785 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
|
2019-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
98,800 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
|
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,750 |
116,682 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
|
2019-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,859 |
72,592 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
|
2020-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
69,995 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
|
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
84,968 |
0 |
- |
|
ADMS |
Adamas Pharmaceuticals In... |
Director |
|
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
EVP and CFO |
|
2020-06-18 |
4 |
A |
$8.36 |
$84 |
D/D |
10 |
10 |
0 |
- |
|
RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
|
2020-10-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
0 |
- |
|
RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
45,500 |
0 |
- |
|
ADMS |
Adamas Pharmaceuticals In... |
Director |
|
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
0 |
- |
|
RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
|
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
52,228 |
0 |
- |
|
RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
|
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
71,808 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Senior VP and CFO |
|
2014-03-25 |
4 |
AS |
$25.69 |
$128,433 |
D/D |
(5,000) |
29,824 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2014-04-25 |
4 |
AS |
$24.13 |
$120,725 |
D/D |
(5,000) |
24,824 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2014-05-29 |
4 |
AS |
$23.00 |
$115,000 |
D/D |
(5,000) |
19,824 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2014-06-18 |
4 |
AS |
$29.95 |
$110,995 |
D/D |
(3,706) |
16,118 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2014-06-25 |
4 |
AS |
$28.52 |
$142,600 |
D/D |
(5,000) |
11,118 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2014-07-25 |
4 |
AS |
$24.11 |
$120,568 |
D/D |
(5,000) |
6,118 |
0 |
- |
|
PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
|
2014-08-25 |
4 |
AS |
$25.72 |
$131,314 |
D/D |
(5,000) |
1,118 |
0 |
- |
|
73 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|